GIVE THAT GAVIN DUDE CREDIT IN CALI ONE THREAT AND WBA GOT THEIR ACT TOGETHER.. Walgreens Boots Alliance to dispense Mifepristone where 'legally permissible' 18:55 WBA The company said, "We want to be very clear about what our position has always been: Walgreens plans to dispense Mifepristone in any jurisdiction where it is legally permissible to do so. Once we are certified by the FDA, we will dispense this medication consistent with federal and state laws. Providing legally approved medications to patients is what pharmacies do, and is rooted in our commitment to the communities in which we operate."
Stoney, don't conflate a bigger picture call with a short term (very) low volume bounce. The naz is going lower. Mark the post.
NuStar upgraded to Buy at Stifel after 'strong' 2022 results 19:47 NS Stifel analyst Selman Akyol upgraded NuStar Energy to Buy from Hold with a price target of $19.50, down from $20. The firm said the upgrade follows strong 2022 results and comes amid greater confidence in the company's ability to deliver strong results. Stifel expects Corpus Christi volumes to remain robust in 2023 and beyond as the world continues to rely on U.S. crude oil.
YOU MAY HAVE NOTICED WE ARE LOOKING AT SOME SPACS AGAIN... CAN'T SAY WE HAVE BOUGHT ONEBUT WE ARE CERTAINLY LOOKING AND THAT MUST MEAN SOMETHING. GBA UPGRADE: LAZR Luminar Technologies, Inc. $9.890.00(0.00%)11:00 AM 03/06/23 NASDAQ |$USD |Pre-Market:$10.10+0.21(+2.12%)
I've been watching one Spa because they do spas in Cruise ships and cruising is doing well. I rather like the chart set up. I want to buy this name:@$11.20<---------- OSW OneSpaWorld Holdings Limited $11.41-0.06(-0.52%)11:00 AM 03/06/23 NASDAQ |$USD |Post-Market:$11.20-0.21(-1.84%)11:36 AM
You don't need me to tell you the vibe on Apple has gotten much better in the past week. HF's are all back in. (as usual) Bunch of reasons but one new one is a VR headset that maybe their stylizers could fashion as groovy and not awkward. The virtual reality (VR) market didn't have a great 2022, but if Apple's (AAPL) long-rumored headset drops this year, some analysts say it could send VR barreling toward mainstream consumers. In 2022, sales in the VR market were down about 2% year-over-year to $1.1 billion, according to research from NDP, while Meta (META) has reportedlystruggled to retain consumers' interest in its new Meta Quest Pro,cutting prices just last week. However, if Apple enters the market this year as they're expected to, it could start to change how the general public views VR. "In VR, we haven't hit that hockey-stick moment yet, where this is just going to just take off like we saw with smartphones," said IDC Research Director Ramon Llamas. "We're not yet at the place where people look at this and say, 'Wow, I just want to put that on,' but Apple just might help create that hockey-stick moment."
13 days ago Wilson says " Rally has turned into a speculative frenzy " Read: Mike was WRONG and he had to label the markets divergence from his view as something negative thus the frenzy. 13 days later: "the rally can continue. " Thank's Mike!
Look at the futures the day that prick shows up -- I have reached my limit with these brokerage talking heads/
---GUMMY--- Mineralys Therapeutics, Inc. (MLYS) NasdaqGS - NasdaqGS Real Time Price. 18.96-0.18(-0.94%) At close: 04:00PM EST 19.61+0.65(+3.43%)<------ GO TIME VAN! Pre-Market:08:37AM EST
THIS NEWS CAME OUT SAT MON $19-$20 MUTED MOVE... Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC Mineralys Therapeutics, Inc. Sat, March 4, 2023, 4:30 PM EST In this article: MLYS -0.94% Mineralys Therapeutics, Inc. orundrostat demonstrated clinically meaningful blood pressure reduction in individuals with uncontrolled hypertension Obesity was predictive of an enhanced response to lorundrostat with placebo-adjusted systolic BP reduction of 16.7 mmHg with 50mg once-daily dosing Additional clinical trial expected to begin in first half of 2023